Patents by Inventor Stanton F. McHardy

Stanton F. McHardy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190389812
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 26, 2019
    Inventors: Graham BEATON, Stanton F. McHARDY, Ambrosio LOPEZ, JR., Bismarck CAMPOS, Hua-Yu Leo WANG
  • Publication number: 20180244631
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Application
    Filed: February 26, 2016
    Publication date: August 30, 2018
    Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Stanton F. MCHARDY, Francisco Xavier RUIZ, III, Ambrosio LOPEZ, Jr., Bismarck CAMPOS, Hua-Yu Leo WANG
  • Patent number: 9169220
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: October 27, 2015
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
  • Publication number: 20150005328
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 1, 2015
    Inventors: Stanton F. MCHARDY, Richard M. CORBETT, Donald M. MAXWELL, Michael W. TIDWELL, Bismarck CAMPOS, Christopher J. BEMBEN
  • Patent number: 8772345
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: July 8, 2014
    Assignee: Southwest Research Institute
    Inventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
  • Publication number: 20140066421
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Application
    Filed: May 17, 2012
    Publication date: March 6, 2014
    Applicant: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
  • Patent number: 8653108
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: February 18, 2014
    Assignee: Southwest Research Institute
    Inventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
  • Publication number: 20130035351
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Application
    Filed: August 3, 2011
    Publication date: February 7, 2013
    Applicant: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Stanton F. MCHARDY, Richard M. CORBETT, Donald M. MAXWELL, Michael W. TIDWELL, Bismarck CAMPOS, Christopher J. BEMBEN
  • Patent number: 8124639
    Abstract: The present invention relates to a series of substituted bicyclic[3.1.0]heteroaryl amides of the Formula I, wherein A, Q, X, Y, Z and R1-R5 groups are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: February 28, 2012
    Assignee: Pfizer Inc.
    Inventors: Stanton F. McHardy, John A. Lowe, III
  • Publication number: 20100324020
    Abstract: The present invention relates to a series of substituted bicyclic[3.1.0]heteroaryl amides of the Formula I, wherein A, Q, X, Y, Z and R1-R5 groups are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.
    Type: Application
    Filed: August 30, 2010
    Publication date: December 23, 2010
    Inventors: Stanton F. McHardy, John A. Lowe, III
  • Patent number: 7049335
    Abstract: The subject invention provides a compound of the formula I, wherein X, Q, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined. Compounds of formula I have activity as opioid receptor antagonists. The subject invention furthermore provides for pharmaceutical compositions and therapeutic methods comprising compounds of formula I.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: May 23, 2006
    Assignee: Pfizer Inc.
    Inventors: Stanton F. McHardy, Spiros Liras, Steven D. Heck
  • Patent number: 6960609
    Abstract: This invention relates to 1-diphenylmethyl-pyrazole derivatives of formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, R4 and R5 are defined herein, as ligands for opioid receptors, particularly the delta opioid receptor. The compounds of the invention have a broad range of therapeutic uses in the area of addictions, analgesia, immunotherapy, shock and brain injuries, neurological dysfunction, gastrointestinal dysfunction, among others.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: November 1, 2005
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Stanton F. McHardy, Michael G. Vetelino
  • Publication number: 20030087898
    Abstract: The subject invention provides a compound of the formula 1, 1
    Type: Application
    Filed: October 22, 2002
    Publication date: May 8, 2003
    Applicant: Pfizer Inc.
    Inventors: Stanton F. McHardy, Spiros Liras, Steven D. Heck
  • Publication number: 20030069241
    Abstract: This invention relates to 1-diphenylmethyl-pyrazole derivatives of formula (I): 1
    Type: Application
    Filed: July 23, 2002
    Publication date: April 10, 2003
    Inventors: Stanton F. Mchardy, Michael G. Vetelino
  • Patent number: 6444679
    Abstract: The present invention relates to compounds of the formula I, wherein Z1, X, Y, ( )n, R1, R2 and R3 are defined as in the specification, pharmaceutical compositions containing such compounds; and the use of such compounds to treat neurological and gastrointestinal disorders.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: September 3, 2002
    Assignee: Pfizer Inc
    Inventors: Spiros Liras, Stanton F. McHardy
  • Publication number: 20020077323
    Abstract: A method for treating a chemical dependency that involves administering an amount of a delta opioid receptor ligand and a serotonin reuptake inhibitor, the amounts being effective in the combination to treat the dependency, wherein the delta opioid receptor ligand is selected from the group consisting of:
    Type: Application
    Filed: July 9, 2001
    Publication date: June 20, 2002
    Inventors: Stafford McLean, Spiros Liras, Stanton F. Mchardy
  • Patent number: RE40838
    Abstract: The subject invention relates to 2-azabicyclo[3.3.1]nonane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia and eating disorders, among others, as are more fully described herein.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: July 7, 2009
    Assignee: Pfizer Inc.
    Inventors: Jotham W. Coe, Stanton F. McHardy